Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment

V.B.C. Biemans, C.J. van der Woude, G. Dijkstra, A.E. van der Meulen-de Jong, M. Lowenberg, N.K. de Boer, B. Oldenburg, N. Srivastava, J.M. Jansen, A.G.L. Bodelier, R.L. West, A.C. de Vries, J.J.L. Haans, D. de Jong, F. Hoentjen, M.J. Pierik, Dutch Initiative Crohn and Colitis

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)123-134
Number of pages12
JournalAlimentary Pharmacology & Therapeutics
Volume52
Issue number1
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • adalimumab
  • dose intensification
  • induction
  • inflammatory-bowel-disease
  • maintenance therapy
  • DOSE INTENSIFICATION
  • INFLAMMATORY-BOWEL-DISEASE
  • ADALIMUMAB
  • INDUCTION
  • MAINTENANCE THERAPY

Cite this